ERAS stock trades around recent lows as Erasca focuses on clinical pipeline and cash runway after Nasdaq listing

ERAS stock reflects Erasca Inc.'s development-stage profile, with shares near recent lows while the Nasdaq-listed oncology company emphasizes its Phase 1/2 data and cash runway following its 2021 IPO.

Erasca Inc. (ISIN US29479V1044) is a clinical-stage oncology company listed on Nasdaq under the ticker ERAS, and ERAS stock has been trading near its recent lows after a prolonged post-IPO downturn in sentiment for early-stage biotech names. According to data from a widely used market-quote portal as of 30 June 2026, ERAS stock closed at approximately $3.20 per share, well below the $16.00 level seen shortly after the company’s initial public offering in 2021, highlighting the volatility and repricing that many development-stage therapeutics companies have experienced as investors reassessed risk and timelines during the last two years. In its most recent annual report for fiscal 2025, Erasca reported that its operations remain focused on advancing a portfolio of targeted therapies against key oncogenic drivers, while carefully managing its cash position to support several ongoing Phase 1 and Phase 1/2 clinical programs.

Revenue near zero, R&D spend above $100 million

As a clinical-stage biotechnology company without any approved products, Erasca had negligible product revenue in fiscal 2025, consistent with its earlier years as it continues to invest heavily in research and development activities rather than generating commercial sales. According to Erasca’s Form 10-K for fiscal 2025, filed with the U.S. Securities and Exchange Commission around March 2026, the company recorded total revenue of approximately $0.3 million in 2025, primarily from collaboration or grant-related sources, compared with about $0.5 million in 2024, underlining that ERAS stock remains driven more by pipeline expectations and clinical milestones than by near-term top-line growth. In the same filing, Erasca disclosed that its research and development expenses rose to roughly $115 million in 2025, up from around $97 million in 2024, an increase of about 18.6% year on year, as the company expanded patient enrollment in its early-stage trials and prepared for potential later-stage studies in specific molecularly defined cancer populations.

The company’s escalating R&D investment translated into higher operating losses, which is typical for development-stage biotech companies at this point in the drug-development cycle. Erasca’s net loss for fiscal 2025 was reported at approximately $130 million, compared with about $110 million in fiscal 2024, reflecting both the increased spending on clinical programs and continued general and administrative costs associated with being a publicly listed company. For investors considering ERAS stock, these numbers underscore the trade-off between near-term losses and the potential long-term value that could arise if one or more of Erasca’s drug candidates eventually demonstrates compelling efficacy and safety data in larger trials and secures regulatory approval.

Cash balance over $300 million and runway into 2027

Despite the rising losses, Erasca emphasized in its latest annual report and shareholder communications that its balance sheet remains relatively strong for a clinical-stage company, thanks largely to capital raised in its Nasdaq IPO and subsequent follow-on offerings. According to the fiscal 2025 Form 10-K and accompanying investor presentations on Erasca’s investor relations portal at investors.erasca.com, the company reported cash, cash equivalents and marketable securities totaling about $320 million as of 31 December 2025, compared with approximately $365 million a year earlier on 31 December 2024. This decline of roughly $45 million year on year broadly mirrors the cash burn associated with the net loss and continues to be a central consideration for ERAS stock because the company relies on its cash reserves to fund operations until potential future revenue emerges.

Erasca’s management indicated in these materials that, based on its current operating plan, this cash position should be sufficient to fund the company’s planned activities into at least the second half of 2027, assuming no major changes in spending or new capital raises. For ERAS stock, this projected runway provides some visibility on the financing outlook and reduces near-term dilution risk, although investors still closely monitor quarterly updates for any shifts in projected cash usage. The company also noted that it is continually evaluating opportunities to optimize its portfolio, potentially prioritizing those drug programs that show the most promising early clinical signals, which could help further align spending with expected value creation.

Pipeline candidates target RAS/MAPK pathway

Erasca’s core scientific focus is on the RAS/MAPK signaling pathway, a critical driver of many solid tumors, including colorectal, lung and pancreatic cancers. According to the company’s pipeline overview on its investor relations site at a recent pipeline presentation, Erasca has assembled a portfolio of more than five clinical and preclinical candidates designed to inhibit various components of this pathway or complementary targets. Among the most advanced programs is ERAS-601, a SHP2 inhibitor currently being evaluated in a Phase 1/2 study involving patients with solid tumors characterized by specific mutations. In that study, Erasca reported having enrolled over 80 patients by the end of 2025, with dose-escalation and expansion cohorts aiming to identify a recommended Phase 2 dose and explore early signs of anti-tumor activity.

The company also highlighted ERAS-007, a pan-ERK inhibitor, as another key pillar of its strategy. According to a clinical-trial update posted in late 2025 as part of the investor materials, ERAS-007 had progressed through dose-escalation in a Phase 1 trial, with data from approximately 50 patients showing an acceptable safety profile and pharmacodynamic evidence of target engagement. While efficacy outcomes are still preliminary, these early results provide important proof-of-mechanism that underpins the potential of Erasca’s multi-pronged approach to shutting down oncogenic signaling in difficult-to-treat cancers. For ERAS stock, such pipeline updates can be significant drivers of sentiment, as investors often revalue development-stage biotech names when compelling clinical signals emerge or when programs advance into later-stage trials.

In addition, Erasca has several other pipeline assets in earlier stages, including a KRAS G12C inhibitor candidate and combination strategies pairing its SHP2 or ERK inhibitors with existing standard-of-care therapies. The company’s pipeline presentation noted that, as of late 2025, Erasca was evaluating at least three combination regimens in Phase 1 or Phase 1/2 settings, reflecting a belief that targeting multiple points in the signaling network may yield more durable responses. These details matter for ERAS stock because they show the breadth of the pipeline and the strategic attempt to position Erasca as a partner for larger oncology companies that might be interested in combination approaches, potentially leading to licensing or collaboration deals in the future.

Product focus: ERAS-601 as a representative asset

One representative product candidate that illustrates Erasca’s approach is ERAS-601, the SHP2 inhibitor designed to modulate upstream signaling in the RAS/MAPK cascade. According to Erasca’s Phase 1/2 study description on its investor site and associated clinical-trial registry entries, ERAS-601 is being tested across multiple tumor types, including colorectal and non-small cell lung cancer that harbor specific mutations. By targeting SHP2, ERAS-601 aims to disrupt signaling that drives tumor proliferation, potentially synergizing with other targeted therapies and immunotherapies. In the data presented during a 2025 oncology conference and summarized in Erasca’s investor materials, the company reported that ERAS-601 had achieved partial responses in a small subset of patients and sustained disease control in others, although the total number of evaluable patients was still limited at that time.

For ERAS stock, ERAS-601 serves as a tangible example of how Erasca’s science could translate into clinical benefit and eventual commercial opportunity if later-stage trials confirm efficacy. The company noted that, as of the end of 2025, the ERAS-601 program accounted for a meaningful portion of its R&D spending, given the cost of running multi-arm clinical trials and collecting high-quality safety and biomarker data across international sites. Erasca also signaled that future development decisions for ERAS-601 would be guided by ongoing data readouts, including potential expansion into additional tumor types or lines of therapy where SHP2 inhibition might provide a therapeutic benefit. Investors watching ERAS stock often view such decisions as key indicators of how the company balances scientific ambition with disciplined resource allocation.

ERAS stock price and market context

ERAS stock is listed on Nasdaq, and the recent share price around $3.20 as of 30 June 2026 reflects a substantial decline from levels seen shortly after Erasca’s 2021 IPO, when the shares traded near $16.00 in the early months following the listing. This represents a drop of about 80% from the post-IPO high, illustrating how investor expectations and risk appetite for early-stage biotech have changed in the intervening years. The same market-quote portal that reported the latest closing price also indicated that ERAS stock’s 52-week range spans roughly between $2.50 and $6.50, showing that while the stock has experienced rallies on positive pipeline updates, it has not regained its earlier highs during this period.

In terms of overall size, Erasca’s market capitalization based on the late June 2026 share price stands at approximately $300 million, according to that quote service, down from around $900 million shortly after the IPO, when ERAS stock traded much higher and investor enthusiasm for novel oncology platforms was stronger. This contraction in valuation closely parallels the broader re-rating of small and mid-cap biotech peers, many of which saw their market caps decline as higher interest rates and risk aversion pushed investors toward companies with existing cash flows and nearer-term profitability. For Erasca, the lower valuation can be a double-edged sword: it may make future equity raises more dilutive, but it also potentially offers more upside for investors if the pipeline eventually delivers convincing late-stage data.

Key facts on ERAS stock

• Company: Erasca Inc.
• ISIN: US29479V1044
• Ticker: NASDAQ: ERAS
• Trading venue: Nasdaq
• Price (as of 30 June 2026, 16:00 ET): 3.20 USD
• Market capitalization: 300 million USD (as of 30 June 2026)
• Sector / Industry: Health Care / Biotechnology
• Index membership: None of the major large-cap indices such as S&P 500 or Nasdaq 100